Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 1/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3218661 | 1.00 | LSS (0.56) | LSSCHRNA7BCHEACHECHRM2 | |
| SCHEMBL3218495 | 1.00 | LSS (0.56) | LSSCHRNA7BCHEACHECHRM2 | |
| SCHEMBL5403372 | 0.93 | LSS (0.55) | LSSCHRNA7BCHEACHECHRM2 | |
| SCHEMBL5390767 | 0.93 | LSS (0.55) | LSSCHRNA7BCHEACHECHRM2 | |
| SCHEMBL5396813 | 0.93 | LSS (0.55) | LSSCHRNA7BCHEACHECHRM2 | |
| Hydrochloric Acid SCHEMBL5653334 | 0.92 | LSS (0.53) | LSSCHRNA7BCHEACHECHRM2 | |
| Hydrochloric Acid SCHEMBL5653510 | 0.92 | LSS (0.53) | LSSCHRNA7BCHEACHECHRM2 | |
| Hydrochloric Acid SCHEMBL5652765 | 0.92 | LSS (0.53) | LSSCHRNA7BCHEACHECHRM2 | |
| SCHEMBL4204692 | 0.90 | LSS (0.55) | LSSCHRNA7 | |
| SCHEMBL5404060 | 0.87 | CHRNA7 (0.52) | LSSCHRNA7BCHEACHECHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3978221-A | TROPINE BENZOHYDRYL ETHER, 3-QUINUCLIDINYL BENZOHYDRYL ETHER | SMITHKLINE CORPORATION (US) | 1976-08-31 | — | — | US | claimed |
| US-7674794-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2010-03-09 | — | — | US | disclosed |
| US-20100056565-A1 | Heterocyclic Derivatives as M3 Muscarinic Receptors | ARGENTA DISCOVERY LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100056565-A1 | Heterocyclic Derivatives as M3 Muscarinic Receptors | ARGENTA DISCOVERY LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100056565-A1 | Heterocyclic Derivatives as M3 Muscarinic Receptors | ARGENTA DISCOVERY LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| US-7655657-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2010-02-02 | — | — | US | disclosed |
| EP-2121688-A1 | HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS | Argenta Discovery Ltd (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008099186-A1 | HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS | ARGENTA DISCOVERY LIMITED (GB) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008099186-A1 | HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS | ARGENTA DISCOVERY LIMITED (GB) | 2008-08-21 | — | — | WO | disclosed |
| US-20080064703-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
| US-5776981-A | Use of acyl urea compounds for controlling endoparasites and ectoparasites of warm-blooded animals | NOVARTIS CORPORATION (US) | 1998-07-07 | — | — | US | disclosed |
| US-5776982-A | Use of acyl urea compounds for controlling endoparasites and ectoparasites of warm-blooded animals | NOVARTIS CORPORATION (US) | 1998-07-07 | — | — | US | disclosed |
| US-5420163-A | Insecticides or miticides | CIBA-GEIGY (US) | 1995-05-30 | — | — | US | disclosed |
| US-5258392-A | 3-quinuclidine derivatives | AKZO N.V. (NL) | 1993-11-02 | — | — | US | disclosed |
| EP-0497415-A1 | 3-Quinuclidine derivatives | Akzo Nobel N.V. (NL) | 1992-08-05 | — | — | EP | disclosed |
| US-5135953-A | Oral or injections; cattle, swine, poultry | CIBA-GEIGY (US) | 1992-08-04 | — | — | US | disclosed |
| EP-0458214-A1 | Bicyclic 1-azacycloalcanes | BOEHRINGER INGELHEIM KG (DE) | 1991-11-27 | — | — | EP | disclosed |
| US-3978221-A | TROPINE BENZOHYDRYL ETHER, 3-QUINUCLIDINYL BENZOHYDRYL ETHER | SMITHKLINE CORPORATION (US) | 1976-08-31 | — | — | US | disclosed |
| US-3978221-A | TROPINE BENZOHYDRYL ETHER, 3-QUINUCLIDINYL BENZOHYDRYL ETHER | SMITHKLINE CORPORATION (US) | 1976-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056565-A1 | Heterocyclic Derivatives as M3 Muscarinic Receptors | CHRM2, CHRM3, CHRM1 | LSS 4700/4885CHRNA7 13/4885BCHE 667/4885 |
| US-20080064703-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | IDO1, IDO2, HTR3C | LSS 2497/4885CHRNA7 144/4885BCHE 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.